GLP-1s & Weight Loss
Semaglutide
← Back to Library
Label-verified Incretin Metabolic
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or human-trial protocol above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 5, 10, 15, 20, 30 mg
Dosing window: Anytime
Receptor / target: GLP-1
Properties: Incretin
Pre-mixed: No
Protocol examples
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 0.25mg once weekly | Initiation phase. Essential to build GI tolerance. |
| Weeks 5-8 | 0.5mg once weekly | First escalation phase. |
| Weeks 9-12 | 1.0mg once weekly | Standard therapeutic threshold. |
| Weeks 13-16 | 1.7mg once weekly | Advanced weight loss phase. |
| Weeks 17+ | 2.4mg once weekly | Maximum clinical research dose. |
Protocol example from the source dataset; verify against the evidence status and listed sources.
Alternative: Split Dosing
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 0.125mg every 3.5 days | E.g., Monday AM and Thursday PM. Flattens plasma levels to reduce nausea. |
| Weeks 5-8 | 0.25mg every 3.5 days | Equals 0.5mg weekly. |
| Weeks 9-12 | 0.5mg every 3.5 days | Equals 1.0mg weekly. |
| Weeks 13+ | 0.85mg every 3.5 days | Equals 1.7mg weekly. |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Alternative: Daily Micro-Dosing
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 0.035mg daily | Daily subQ injections completely stabilize peaks and valleys, virtually eliminating all GI side effects. |
| Weeks 5-8 | 0.07mg daily | Equals ~0.5mg weekly. |
| Weeks 9+ | 0.14mg daily | Equals ~1.0mg weekly. Adjust upward based on appetite suppression. |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Protocol logic check
Protocol context: Weight-loss protocols should not pretend fat loss is only willpower. The logic is appetite signaling, GI tolerance, adherence, protein, resistance training, hydration, and preserving lean mass while the dose changes. Entry context: target (GLP-1); route Subcutaneous; timing Anytime. Label/trial anchors carry more weight than forum-style escalation. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. Common diet-myth context matters: rapid vs slow loss is individual, fasting only helps when adherence improves, and protein/training protect lean mass during aggressive deficits.
Independent evidence
Approved label dosing: Wegovy injection starts at 0.25 mg SC once weekly for 4 weeks, escalates every 4 weeks through 0.5 mg, 1 mg, and 1.7 mg, then maintenance depends on indication; adult weight reduction commonly uses 1.7 mg or 2.4 mg once weekly, with 2.4 mg recommended in many contexts. 2026 label also includes Wegovy HD 7.2 mg for selected additional weight reduction after tolerance to 2.4 mg.
Clinical trial regimen(s): STEP 1: semaglutide 2.4 mg SC once weekly plus lifestyle intervention for 68 weeks.
Independent safety notes: FDA warns that compounded semaglutide products can create dosing errors and that compounded drugs are not FDA-approved. | FDA states semaglutide salt forms are different active ingredients from approved semaglutide products and lacks a lawful basis for their use in compounding.
Regulatory status: approved drug label available
Storage
Single-dose pen/syringe: refrigerate 2-8 C; may be kept 8-30 C up to 28 days before cap removal; protect from light; do not freeze. FlexTouch has separate in-use storage limits.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Personal or family history of Medullary Thyroid Carcinoma (MTC).
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Personal or family history of thyroid C-cell tumors.
- Active or history of acute pancreatitis.
- Type 1 diabetes mellitus.
- Diabetic ketoacidosis.
- Severe gastroparesis or clinically significant delayed gastric emptying.
- Pregnancy: manufacturer advises discontinuation at least 2 months prior to planned conception due to potential fetal risk.
- Breastfeeding: insufficient safety data; potential risk of transfer to infant.
- Known hypersensitivity or anaphylaxis to semaglutide or any formulation excipient.
- Concurrent use with other GLP-1 receptor agonists (e.g., liraglutide, dulaglutide, exenatide): overlapping mechanism with additive adverse effects.
- Concurrent use with tirzepatide, retatrutide, or any dual/triple incretin agonist: direct pharmacological conflict.
- History of suicidal ideation or prior suicide attempts: monitor closely.
- Planned general anesthesia or elective surgery: delayed gastric emptying raises risk of pulmonary aspiration; follow pre-operative fasting protocols.
- Pediatric use under age 12: safety and efficacy not established.
- End-stage renal disease on dialysis: limited clinical evidence; use with extreme caution.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Nausea: most prevalent adverse effect; reported in up to 44% of subjects at higher doses.
- Vomiting.
- Diarrhea.
- Constipation.
- Abdominal pain and cramping.
- Dyspepsia (indigestion).
- Abdominal distension and bloating.
- Decreased appetite and dysgeusia (altered taste).
- Belching and flatulence.
- Gastroparesis: delayed gastric emptying that may persist even with pre-operative fasting.
- Gastroesophageal reflux disease (GERD) exacerbation.
- Fatigue and lethargy: frequently secondary to acute caloric deficit rather than direct drug toxicity.
- Headache.
- Dizziness.
- Hypoglycemia: risk significantly elevated when combined with insulin, sulfonylureas, or other glucose-lowering agents.
- Acute pancreatitis: documented in case reports and clinical trials.
- Acute kidney injury: primarily mediated by dehydration from GI side effects.
- Cholelithiasis (gallstones) and acute cholecystitis: risk increases with dose and duration.
- Diabetic retinopathy complications: risk elevated in subjects with pre-existing retinopathy during rapid glycemic correction.
- Nonarteritic anterior ischemic optic neuropathy (NAION): reported in post-marketing and retrospective cohort data; causality not confirmed.
- Thyroid C-cell tumor risk: confirmed in rodent models; human risk unclear; monitor for neck mass, hoarseness, or dysphagia.
- Alopecia (hair loss): reported in post-marketing surveillance.
- Injection site reactions: redness, itching, bruising at administration site.
- Anaphylaxis and angioedema: rare but documented.
- Pulmonary aspiration risk under general anesthesia: secondary to delayed gastric emptying.
- Rapid weight regain upon discontinuation: approximately two-thirds of lost weight regained within one year without lifestyle maintenance.
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
Sources
- https://the source dataset.com/peptide-codex.php
- https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- https://pubmed.ncbi.nlm.nih.gov/33567185/
- https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy
- PubMed search: Semaglutide
- DailyMed label search: semaglutide